This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Neil McGowan
Head Of Manufacturing: Tissues, Cells and Advanced Therapeutics at Scottish National Blood Transfusion Service, UK


Neil McGowan graduated with a First Class BSc. (Hons.) in Immunology & Pharmacology from the University of Strathclyde in 1998, after which he gained a PhD in medical science (specifically bone cell biology) from the University of Aberdeen. He moved to London in 2002 to continue his work in the bone cell biology field as a Postdoctoral Research Associate at King's College London.

He joined the Scottish National Blood Transfusion Service (SNBTS) in 2005, after following a desire to enter a more clinical-based field.  There he initially worked as a Tissue & Cells Scientist, covering the broad range of roles involved in the procurement, testing, manufacture, storage and issue of a range of live and cadaveric tissue and cell products, before being promoted to Glasgow Tissue Bank Laboratory Manager in 2007. 

He returned to Edinburgh in 2009 after being appointed Laboratory Manager of the Clinical Islet Cell Laboratory, overseeing the establishment of this cellular therapy in Scotland. In 2013 he moved to a new role as Cell Therapy Project Manager for the SNBTS based at the University of Edinburgh Scottish Centre for Regenerative Medicine (SCRM) and in 2017 has become the Head of Manufacturing for Advanced Tissues, Cells and Advanced Therapeutics in SNBTS.

Within this role he is responsible for the GMP translation, manufacture and QC of a range of tissue, cell and novel advanced therapeutics through to clinical trials within HTA and MHRA-licensed facilities at both the SCRM and the Jack Copland Centre.  He is also currently training to become a Qualified Person that can certify the release of advanced therapeutics in accordance with EU law.

Agenda Sessions

  • Facilities for the future: design & qualification of aseptic manufacturing facilities for cell and gene therapy


Speakers at this event